Findings showed that histology may influence the efficacy of different chemotherapeutic regimens, as adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors were shown to have better disease control and treatment response rates than patients diagnosed with squamous cell carcinoma or other non-adenocarcinoma subtypes [45]. Here, EGFR is linked to squamous cell carcinoma.